SARS-CoV-2-specific Cell-mediated Immunity in Kidney Transplant Recipients Recovered From COVID-19. Issue 6 (June 2021)

• Record Type: Journal Article
• Authors: Fernández-Ruiz, Mario; Olea, Beatriz; Giménez, Estela; Laguna-Goya, Rocío; Trujillo, Hernando; Caravaca-Fontán, Fernando; Gutiérrez, Eduardo; López-Medrano, Francisco; Remigia, María José; Almendro-Vazquez, Patricia; Polanco, Natalia; González, Esther; Ruiz-Merlo, Tamara; Parra, Patricia; San Juan, Rafael; Andrés, Amado; Navarro, David; Aguado, José María
• Is Part Of: Transplantation. Volume 105:Issue 6(2021)
• Publication Date: 2021-06
• Subjects: Transplantation of organs, tissues, etc -- Periodicals; Transplantation immunology -- Periodicals; 617.95
• DOI: 10.1097/TP.0000000000003672
• Languages: English
• ISSNs: 0041-1337

Abstract

Abstract : Background: The magnitude and kinetics of severe acute respiratory syndrome coronavirus 2–specific cell-mediated immunity (SARS-CoV-2-CMI) in kidney transplant (KT) recipients remain largely unknown. Methods: We enumerated SARS-CoV-2-specific interferon-γ-producing CD69 + CD4 + and CD8 + T cells at months 4 and 6 from the diagnosis of coronavirus disease 2019 (COVID-19) in 21 KT recipients by intracellular cytokine staining. Overlapping peptides encompassing the SARS-CoV-2 spike (S) glycoprotein N-terminal 1- to 643-amino acid sequence and the membrane protein were used as stimulus. SARS-CoV-2 IgG antibodies targeting the S1 protein were assessed by ELISA at month 6. Results: Detectable (≥0.1%) SARS-CoV-2-specific CD4 + T-cell response was found in 57.1% and 47.4% of patients at months 4 and 6. Corresponding rates for CD8 + T cells were 19.0% and 42.1%, respectively. Absolute SARS-CoV-2-specific T-cell counts increased from month 4 to month 6 in CD8 + ( P = 0.086) but not CD4 + subsets ( P = 0.349). Four of 10 patients with any detectable response at month 4 had lost SARS-CoV-2-CMI by month 6, whereas 5 of 9 patients mounted SARS-CoV-2-CMI within this period. All but 2 patients (89.5%) tested positive for SARS-CoV-2 IgG. Patients lacking detectable SARS-CoV-2-specific CD4 + response by month 6 were more likely to be under tacrolimus (100.0% versus 66.7%; P = 0.087) and to have received tocilizumab for the previous COVID-19 episode (40.0% versus 0.0%; P = 0.087). Conclusions: Although still exploratory and limited by small sample size, the present study suggests that a substantial proportion of KT recipients exhibited detectable SARS-CoV-2-CMI after 6 months from COVID-19 diagnosis. Abstract : Supplemental Digital Content is available in the text.